Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cangrelor - Chiesi Farmaceutici

Drug Profile

Cangrelor - Chiesi Farmaceutici

Alternative Names: AR-C 69931; AR-C69931MX; CHF 6727; Kengreal; Kengrexal

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Adenine nucleotides; Antiplatelets; Phosphonic acids; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Coronary artery disease; Coronary thrombosis
  • No development reported Acute coronary syndromes

Most Recent Events

  • 13 Nov 2020 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Coronary thrombosis (In neonates, Prevention) presented at the American Heart Association (AHA-2020)
  • 28 Feb 2020 No recent reports of development identified for phase-I development in Coronary-thrombosis(In neonates, Prevention) in USA (IV, Infusion)
  • 23 Dec 2019 Chiesi Farmaceutici completes a phase I trial in Coronary thrombosis (In neonates, Prevention) in USA (IV) (NCT02765633)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top